AMDL Launches Expanded Distribution With 4th Round of Agreements Valued at $6.79 Million Annually for New Health & Beauty Produc

TUSTIN, Calif., Nov. 7 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), which is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products, announced today that JPI's subsidiary JJB has signed the fourth round of regional distribution agreements for its new anti-aging and skin care injectable product under the brand name "Goodnak." This initial product is the first in a new line of anti-aging & skin care products currently under development by JJB.

JJB has signed three new Central Region exclusive, one-year renewable Distribution and Agency Agreements that were signed between Jade Pharma's subsidiary JJB and Henan Yinji Bio-chemistry Co., Ltd. ("HYB"), Chengdu Fairyland Cosmetics Co., Ltd. and ("CFC"), Guizhou Camry Beauty Technology Co., Ltd. ("GCB"). These agreements cover the key cities in Henan, Sichuan and Guizhou Provinces that have a combined population of approximately 134.4 million people. These two separate agreements in combination, require these new distributors to purchase a minimum of US$6,790,944 of JJB's new HPH product during the one-year period of the contracts and a minimum initial order of US$4,061,250.

Frank Zheng, managing director of JPI, said this fourth round of additional distribution agreements, coupled with the previously announced agreements, puts the Company on the path to building sales of Goodnak by as much as $24 million over the next 12 months. Gary Dreher, CEO of AMDL said the Company expects to further update the market on its expansion plans in the coming weeks.

About Goodnak: Goodnak is a high quality injectable anti-aging & skin care product that contains an amalgam of various therapeutic elements including human placental histosolution ("HPH"). JPI has begun selling Goodnak, in August, through wholesale distribution channels that service high-end beauty salon and plastic surgery hospitals and or medical cosmetology institutions. Goodnak product information is available on Jade Pharma's product specific website: http://www.jade-amdl.com.

About JPI: Jade Pharmaceutical through its subsidiaries JJB & YYB has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injectable fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

SOURCE AMDL, Inc.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.